Who is sponsoring NCT05434455?

NCT05434455 is sponsored by Shanghai Zhongshan Hospital.

What condition does NCT05434455 study?

NCT05434455 studies Postoperative Delirium, Cardiac Surgery.

Is NCT05434455 still recruiting?

NCT05434455 is currently status unknown. Last updated 30 June 2022.

Last reviewed 2022-06-30 · How we verify

NCT05434455

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of RIPC on the Prevention of POD in Patients Undergoing Cardiac Surgery

Status unknown NA Last updated 30 June 2022

What this trial tests

NA trial testing RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion in Postoperative Delirium in 216 participants. Status unknown.

Timeline

1 July 2022

Primary endpoint
14 July 2022

31 December 2023

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	prevention
Enrollment	216
Start date	1 July 2022
Primary completion	14 July 2022
Estimated completion	31 December 2023

Drugs / interventions tested

RIPC induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion

Conditions studied

Postoperative Delirium — all drugs for Postoperative Delirium →
Cardiac Surgery — all drugs for Cardiac Surgery →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 80, any sex, with Postoperative Delirium or Cardiac Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postoperative delirium (POD) is one of the most frequent neurological complications in elderly patients and is closely associated with longer ICU stay and hospitalization, deterioration of long-term neurocognitive function, and increased mortality. The incidence of POD is significantly higher in elderly patients undergoing cardiac surgery than in other populations. Therefore, the prevention of POD is an important clinical problem to be solved urgently. In this study, we intend to observe the effect of RIPC on the prevention and treatment of POD in patients undergoing cardiac surgery through a prospective randomized controlled trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05434455 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 30 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05434455.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing